THURSDAY, May 8, 2025 (HealthDay News) — Ultra-hypofractionated (UHF) radiotherapy delivered over two weeks is noninferior to conventionally fractionated (CF) radiotherapy delivered over eight weeks for localized prostate cancer up to 10 years, according to a study presented at the annual meeting of the European Society for Radiotherapy and Oncology, held from May 2 to […]
The post Ultra-Hypofractionated Radiotherapy Noninferior for Prostate Cancer first appeared on Physician’s Weekly.
